Eris Lifesciences share news, announcements and annual reports
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Eris Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2017 · Issue price ₹603
Last close ₹1,156.40down ₹7.20 (0.62%)BSE ₹1,159.60
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,163.60.
30 Oct: open ₹1,163.00, high ₹1,174.70, low ₹1,148.00
52-week range of traded prices to 30 Oct 2026
₹1,069.00Low, 26 Oct 2026₹1,740.00High, 9 Dec 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,044 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.67
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.87
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 31,21340.7% delivered
Eris Lifesciences shareholding disclosures
43 filed, newest first.
Jul 2026
30 Jul · Disclosure
Jun 2026
26 Jun · Disclosure
May 2026
11 May · Disclosure
Mar 2026
12 Mar · Disclosure
Nov 2025
17 Nov · Disclosure
Aug 2025
30 Aug · Disclosure
Jul 2025
21 Jul · Disclosure
Jun 2025
5 Jun · Disclosure
Apr 2025
24 Apr · Disclosure
Mar 2025
6 Mar · Disclosure
Aug 2024
14 Aug · Disclosure
Jun 2024
24 Jun · Disclosure
May 2024
24 May · Disclosure
Apr 2024
9 Apr · Disclosure
Dec 2023
22 Dec · Disclosure
Aug 2023
24 Aug · Disclosure
Jul 2023
7 Jul · Disclosure
Apr 2023
10 Apr · Disclosure
Mar 2023
2 Mar · Disclosure
Sep 2022
9 Sep · Disclosure
Jun 2022
21 Jun · Disclosure
Apr 2022
14 Apr · Disclosure
Dec 2021
21 Dec · Disclosure
Sep 2021
24 Sep · Disclosure
May 2020
Apr 2019
Feb 2019
18 Feb · Disclosure
Nov 2018
20 Nov · Disclosure
Aug 2018
16 Aug · Disclosure
Apr 2018
21 Apr · Disclosure